Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
aerosolized vancomycin or gentamicin · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| aerosolized vancomycin or gentamicin | DRUG | - |
Inclusion Criteria: * be on mechanical ventilation greater than 3 days * greater than or equal to 18 years of age survival greater than 14 days * greater than 2 ccs of tracheal secretions/4 hours Exclusion Criteria: * allergy to drugs, pregnancy
Aerosolized vancomycin or gentamicin is used for Ventilator Associated Pneumonia, a lung infection that occurs in people on mechanical ventilation. It is also being studied for respiratory infection and tracheobronchitis. The drug is delivered directly to the lungs as an aerosol.
Nektar Therapeutics (NASDAQ: NKTR) is developing aerosolized vancomycin or gentamicin. The company is conducting clinical research on this antibiotic combination for the treatment of Ventilator Associated Pneumonia in patients on mechanical ventilation.
Aerosolized vancomycin or gentamicin is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial has been completed, with 80 patients enrolled.
Aerosolized vancomycin or gentamicin has one completed Phase 2 trial, NCT00396578, titled "Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation." The trial enrolled 80 participants in the United States with Ventilator Associated Pneumonia, respiratory infection, or tracheobronchitis.
Aerosolized vancomycin or gentamicin targets bacterial infections in the respiratory tract. Vancomycin and gentamicin are antibiotics that work against different types of bacteria, and delivering them as an aerosol aims to treat infections like Ventilator Associated Pneumonia directly in the lungs.
Aerosolized vancomycin or gentamicin is a combination of two antibiotics, vancomycin and gentamicin, formulated for inhalation. It is distinct from standard intravenous or oral forms of these drugs because it is delivered directly to the lungs as an aerosol for respiratory infections.